<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541618</url>
  </required_header>
  <id_info>
    <org_study_id>MSDX-0411</org_study_id>
    <nct_id>NCT01541618</nct_id>
  </id_info>
  <brief_title>A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis</brief_title>
  <official_title>A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MSDx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MSDx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients
      before and after beginning Natalizumab.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MSDX Complex-1 between baseline and 6-month visit</measure>
    <time_frame>6 months</time_frame>
    <description>This outcome measure will evaluate a difference in the level of MSDX Complex-1 form the baseline visit to the 6-month visit. MSDX Complex-1 is a biomarker for MS disease activity and its change should correspond with a change in the disease activity in MS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gadolinium MRI and MSDX Complex-1 level</measure>
    <time_frame>6 months</time_frame>
    <description>This outcome will evaluate whether a change seen in a Gadolinium MRI (a diagnostic test for MS) matches with a change in the MSDX Complex-1 level in a patient with MS.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Tysabri Group</arm_group_label>
    <description>Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MSDX Complex-1 Biomarker test</intervention_name>
    <description>MSDX Complex-1 Biomarker test</description>
    <arm_group_label>Tysabri Group</arm_group_label>
    <other_name>Biomarker Test</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood remaining after the biomarker test is completed will be retained for possible
      evaluation of additional biomarkers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study populations for this study is a patient with a diagnosis of relapsing remitting
        multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse
        in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of clinically definite relapsing remitting MS (RRMS)

          2. Age 45 years and older

          3. Willing and able to provide written informed consent

          4. Patient has high disease activity.

          5. Patient is about to begin Natalizumab (Tysabri) therapy.

        Exclusion Criteria:

          1. Any clinically significant disease other than MS that is likely to interfere with the
             evaluation of CDMS

          2. Known infectious or hematological disease.

          3. Unwilling or unable to comply with the requirements of this protocol

          4. Subject can not have a gadolinium enhanced MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeannette Wendt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwest NeuroSpecialists, PLLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Wesselhoft</last_name>
    <email>mwesselhoft@msdx.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramesh Nayak, PhD</last_name>
    <email>rnayak@msdx.co</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwest NeuroSpecialists, PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Wendt, MD</last_name>
      <phone>520-742-7890</phone>
    </contact>
    <investigator>
      <last_name>Jeanette Wendt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>February 29, 2012</last_update_submitted>
  <last_update_submitted_qc>February 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>RRMS</keyword>
  <keyword>RR Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

